口服藥物治療子宮頸癌前病變？

Using Oral Drug for the Therapy of Cervical Dysplasia

許多研究認為抑制環氧化酶（cyclooxygenase-2, COX-2）有致癌性質，它會產生細胞增殖、分裂、細胞沾黏、自然凋亡（apotosis）、免疫反應、和血管增生等，使癌細胞加速生長。在人類子宮頸癌前病變，常有COX-2高度顯示，而且病灶有顯示（expression）患者有較高復發比例。口服COX-2抑制劑乃一種非類固醇抗消炎劑，可以選擇抑制COX-2，但可避免胃腸副作用，現可能認為作為治療癌症治療藥物。最近，celecoxib（COX-2抑制劑）被證明可能治療子宮頸癌前病變，甚至能作為癌症預防藥物。

Several studies suggest that cyclooxygenase-2(COX-2) is important in carcinogenesis, it may play a role in cancer progression by affecting cell proliferation, mitosis, cell adhesion, apoptosis, immune surveillance, and angiogenesis. Initial studies in human cervix demonstrate that higher expression of COX-2 in cervical intraepithelial neoplasia(CIN) at surgical excision is associated an increased rate of recurrence. COX-2 inhibitor are a class of non-steroidal anti-inflammatory drugs(NSAIDs) selective for the COX-2 enzyme, whereby significant upper gastrointestinal toxicity is averted when administered orally, making it an attractive potential chemotherapeutic agent. Recent, celecoxib(COX-2 inhibitor) has shown potential as a medical treatment for cervical pre-invasive disease. Future studies into the inhibition of COX-2 when treating pre-invasive disease may play a much larger role on cancer prevention.